Midway into November and well into the second wave of the coronavirus pandemic, health experts are increasingly worried about public mistrust over vaccines, and by the lack of a clear communication strategy to address the many questions being asked by Canadians about a vaccine for COVID-19.
Karyn Methven, a cancer survivor, is terrified of contracting COVID-19. “Gosh, this is really urgent,” says Methven, of Delta, BC. “We’ve hit the10-thousand mark now in Canada, you know. Ten thousand deaths.”
Britt Bright was sick for nearly six months during an influenza pandemic in the 1950s. It left her with permanent lung damage. “I would jump for the COVID [vaccine],” says Bright, a retired psychiatrist from Maple Ridge, B.C.
Courtney Vasquez, a mother of two, says she wants to “wait a few years, see how it plays out,” referring to the development of a vaccine for COVID-19.
These are some of the voices from a town hall recently convened for Global News: The New Reality, to gauge Canadians’ views on a potential vaccine for coronavirus.
Nine Canadians offered their views on a potential vaccine for COVID-19. They were among thousands of people who wrote to Global News about the topic. Their comments, along with new polling data, also confirm a disturbing trend emerging around COVID-19: growing hesitancy over a potential vaccine.
“We found that most people are OK with the idea of getting vaccinated,” says Steven Taylor, a professor in the Department of Psychiatry at the University of British Columbia, who has researched vaccine hesitancy.
Story continues below advertisement
“But the number of people who are becoming hesitant seems to be rising.”
It’s still likely months before scientists complete clinical trials on potential COVID-19 vaccines, and public opinion could change in the meantime.
6:37 Coronavirus: World Health Organization looking at middle 2021 as likely roll-out of vaccine
Coronavirus: World Health Organization looking at middle 2021 as likely roll-out of vaccine – Oct 19, 2020
While Health Canada says that Canadians should have confidence in the process, the federal department is still working on a plan with the provinces to address misinformation, confusion and unanswered questions from the population.
That messaging plan hasn’t rolled out yet, says Dr. Supriya Sharma, the federal department’s chief medical advisor, “but it will be coming out fairly, fairly soon.”
It isn’t clear whether this will be soon enough.
Slim majority willing to take vaccine when available
Story continues below advertisement
According to a survey carried out for Global News between October 23-26 by the polling firm Ipsos, just 54 per cent of the Canadian public is willing to take a vaccine as soon as they can. Of that figure, only 22 per cent feel strongly about taking a vaccine right away.
The poll also found that just 61 per cent of respondents support mandatory vaccination for COVID-19, down from 72 per cent who supported a mandatory vaccination program just four months ago.
“This vaccine […] is going to honestly be a sign of how much we trust our doctors, how much we trust our government and our politicians, and how much we trust the media on this,” according to Serena Crowder, a mother of four who spoke at the Global’s town hall, from Georgina, Ont.
Taylor from UBC says public health authorities should have launched a communications plan about vaccines months ago.
“We knew this was going to be a problem,” he says.
Rumour cost $500 million
Heidi Larson has travelled the world, working for the United Nations, fighting rumours that vaccines are somehow harmful.
She warns that a failure to anticipate and address doubts and misinformation could have disastrous consequences.
“The most dramatic example that I saw was just a rumour in Northern Nigeria, driven by political distrust,” says Larson, the founding director of the Vaccine Confidence Project, a research group based in London, England.
She says this rumour triggered resistance to a vaccination campaign against polio in Nigeria. It allowed the disease to spread through 20 countries and “cost the global polio program $500 million to reset the clock,” she says.
‘Operation Warp Speed’
Taylor also says that public officials should be careful about how they describe or label new vaccine projects.
“If you’re going to call your vaccine development program something like ‘Operation Warp Speed,’ which is the name of the program in the United States, that implies that things have been rushed,” Taylor says.
Instead, he said governments should emphasize the safety of the process, as opposed to its speed. “Vaccination development and dissemination programs with more reassuring titles would be more likely to engage the public trust (e.g., calling the program ‘Operation Due Diligence’ instead of ‘Operation Warp Speed’),” he wrote, in a recently co-authored journal paper.
Story continues below advertisement
Canada has one of the strongest regulatory systems in the world for developing and approving new vaccines.
Under this system, three federal scientific teams review a vaccine prior to approving or rejecting it. Sharma, from Health Canada, says one team looks at pre-trial research on animals, a second team reviews human clinical trials, and a third team reviews the manufacturing process.
Sharma also notes that the department’s review of potential COVID-19 vaccines will be “the same as with any other vaccine.”
So if the department determines a vaccine candidate doesn’t mean the standards, Health Canada will not approve it, she explains.
“There’s a lot of information that’s not accurate,” Sharma says. “There’s just such a volume of information coming at people. I think it’s awesome and challenging to find out what’s trustworthy information, versus something that people are just sending around.”
Values-based approach
Saad Omer, director of Yale University’s Institute for Global Health, warns that governments should not assume people will take the vaccine.
“There was this naïve belief in the spring that all of a sudden people will start accepting this vaccine because everyone is talking about [COVID-19],” says Omer, the director of Yale University’s Institute for Global Health.
Story continues below advertisement
Whether dealing with vaccine hesitancy or climate change skepticism, the challenge for communicators is to reinforce the message that the science is sound, but also to meet people where they are at in terms of their values, Omer explains.
“You can’t change people’s values, and you shouldn’t try to change people’s values. But you can speak to people’s values,” Omer said.
2:20 The difficult fight of dispelling myths about vaccines
The difficult fight of dispelling myths about vaccines – Apr 4, 2019
Pharma pledge
The pharmaceutical industry is also taking steps to boost public confidence in their efforts. In September, the CEOs of nine pharmaceutical companies signed apledge to adhere to accepted scientific standards in the hunt for the vaccine.
“We’re not cutting corners at all. We’re taking our time, and that’s why the vaccine is not available right now, because it takes time,” Jean-Pierre Baylet, general manager of Sanofi Pasteur Canada, told Global News’ The New Reality.
Story continues below advertisement
Whatever findings the pharmaceutical companies come up with in clinical trials will ultimately need to be shared with Health Canada for scrutiny and review.
“I understand why there’s some hesitation,” says Dr. Sharma, the medical advisor at Health Canada. But, she adds, “we have a very strong system of review […] no vaccine will be sent out for the Canadian public unless it gets authorized by Health Canada, and they should have confidence in the system.”
Shifting the focus
At the moment, billions are being invested in developing a vaccine. But, says Yale’s Saad Omer, a coordinated public education campaign is falling by the wayside.
“This is a substantial public health catastrophe,” he says. “And the moment should be matched by the size and the reach of a systematic public health campaign that clarifies the vaccine development and approval process, that talks about what is known and what is unknown.”
3:00 COVID-19 vaccine in development showing promise in adults
COVID-19 vaccine in development showing promise in adults – Oct 26, 2020
Populist politicians around the world, alongside a few celebrities, are filling the void with misleading information alongside all sorts of conspiracy theories.
It isn’t just the public at large, either, that is vaccine-hesitant. Mistrust over a coronavirus vaccine also runs through the health care community, amplifying the communication challenge even more.
“Health care providers,” says Omer, “need information and training in communicating around this vaccine. That’s not being done in most countries in the world, and that’s one of the things that keeps me up at night.”
Both Omer and Heidi Larson, of the Vaccine Confidence Project, agree that the way to instill confidence is through engagement at the community level, with voices that people can trust.
“It’s about caring about people,” Larson says. “It’s about caring about their emotions and feelings, and why they feel like they’re hesitant, because that’s a big problem right now.”
At the same time, she says it’s a “huge opportunity” to set the record straight on vaccines and to instill confidence.
“If we get this wrong, that will not be forgotten.”
Story continues below advertisement
See this and other original stories about our world on The New Reality airing Saturday nights on Global TV, and online.
TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.
Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.
Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).
SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.
The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.
WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.
SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.
SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.
SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.
The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.
Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.
“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.
“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”
Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.
On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.
If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.
These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.
If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.
However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.
He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.
“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.
Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.
The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.
Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.
Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.
Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.
Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.
Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”
In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.
“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.
This report by The Canadian Press was first published Nov. 12, 2024.
TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.
The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.
The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.
RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.
The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.
RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.
This report by The Canadian Press was first published Nov. 12, 2024.